{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:35:16Z","timestamp":1793673316516,"version":"4.5.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005940","name":"Dansk Kr\u00e6ftforsknings Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005940","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024075","name":"Region Syddanmark","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024075","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Research Council at Lillebaelt Hospital"},{"DOI":"10.13039\/501100005747","name":"A.P. M\u00f8ller og Hustru Chastine Mc-Kinney M\u00f8llers Fond til almene Formaal","doi-asserted-by":"publisher","award":["20-L-0039"],"award-info":[{"award-number":["20-L-0039"]}],"id":[{"id":"10.13039\/501100005747","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Einar Willumsens Memorial Trust"},{"name":"Consultant J\u00f8rgen Werner Schous and wife Else Marie Schous, born Wonges Foundation","award":["853832"],"award-info":[{"award-number":["853832"]}]},{"name":"Master Carpenter J\u00f8rgen Holm and wife Elisa f. Hansens Memorial Trust","award":["20066"],"award-info":[{"award-number":["20066"]}]},{"DOI":"10.13039\/501100003554","name":"Lundbeck Foundation","doi-asserted-by":"publisher","award":["R307-2018-3433"],"award-info":[{"award-number":["R307-2018-3433"]}],"id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006309","name":"Riisfort Fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006309","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Novo Nordisk Foundation ODIN program","award":["NNF20SA0061466"],"award-info":[{"award-number":["NNF20SA0061466"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-34975-4","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T11:05:46Z","timestamp":1770116746000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Transcriptional profiling of the tumor microenvironment of recurrent and non-recurrent stage II colon cancer"],"prefix":"10.1038","volume":"16","author":[{"given":"Ulrik","family":"Korsgaard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Pihlmann","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne Kj\u00e6r","family":"Frifeldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Lindebjerg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torben Fr\u00f8strup","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Hager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lasse Sommer","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"issue":"3","key":"34975_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 71(3), 209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"34975_CR2","unstructured":"WHO Classification of Tumours Editorial Board, WHO classification of digestive system tumours, 5th ed., 1 (World Health Organization, 2019)."},{"issue":"4","key":"34975_CR3","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1055\/s-0035-1564430","volume":"28","author":"A Varghese","year":"2015","unstructured":"Varghese, A. Chemotherapy for Stage II Colon Cancer. Clin. Colon. Rectal. Surg. 28(4), 256\u2013261. https:\/\/doi.org\/10.1055\/s-0035-1564430 (2015).","journal-title":"Clin. Colon. Rectal. Surg."},{"key":"34975_CR4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.3048","author":"LA Pahlman","year":"2016","unstructured":"Pahlman, L. A. et al. Should the Benefit of Adjuvant Chemotherapy in Colon Cancer Be Re-Evaluated?. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO.2015.65.3048 (2016).","journal-title":"J. Clin. Oncol."},{"key":"34975_CR5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.5098","author":"J Nors","year":"2023","unstructured":"Nors, J., Iversen, L. H., Erichsen, R., Gotschalck, K. A. & Andersen, C. L. Incidence of Recurrence and Time to Recurrence in Stage I to III Colorectal Cancer. JAMA Oncol. https:\/\/doi.org\/10.1001\/jamaoncol.2023.5098 (2023).","journal-title":"JAMA Oncol."},{"key":"34975_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2024.04.003","author":"U Korsgaard","year":"2024","unstructured":"Korsgaard, U. et al. The transcriptional landscape of coding and non-coding RNAs in recurrent and non-recurrent colon cancer. Am. J. Pathol. https:\/\/doi.org\/10.1016\/j.ajpath.2024.04.003 (2024).","journal-title":"Am. J. Pathol."},{"key":"34975_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: The next generation. Cell https:\/\/doi.org\/10.1016\/j.cell.2011.02.013 (2011).","journal-title":"Cell"},{"key":"34975_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.02.016","author":"KE de Visser","year":"2023","unstructured":"de Visser, K. E. & Joyce, J. A. The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. Cancer Cell https:\/\/doi.org\/10.1016\/j.ccell.2023.02.016 (2023).","journal-title":"Cancer Cell"},{"key":"34975_CR9","doi-asserted-by":"publisher","DOI":"10.1101\/GAD.314617.118","author":"H Gonzalez","year":"2018","unstructured":"Gonzalez, H., Hagerling, C. & Werb, Z. Roles of the immune system in cancer: From tumor initiation to metastatic progression. Genes Dev. https:\/\/doi.org\/10.1101\/GAD.314617.118 (2018).","journal-title":"Genes Dev."},{"key":"34975_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30789-X","author":"F Pag\u00e8s","year":"2018","unstructured":"Pag\u00e8s, F. et al. International validation of the consensus immunoscore for the classification of colon cancer: A prognostic and accuracy study. The Lancet https:\/\/doi.org\/10.1016\/S0140-6736(18)30789-X (2018).","journal-title":"The Lancet"},{"key":"34975_CR11","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-17-0870","author":"K Wallace","year":"2018","unstructured":"Wallace, K. et al. Tumor-infiltrating lymphocytes and colorectal cancer survival in Africa Namerican and Caucasian Patients. Cancer Epidemiol. Biomark. Prev. https:\/\/doi.org\/10.1158\/1055-9965.EPI-17-0870 (2018).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"34975_CR12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2073","author":"J Forssell","year":"2007","unstructured":"Forssell, J. et al. High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin. Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-2073 (2007).","journal-title":"Clin. Cancer Res."},{"key":"34975_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0047045","author":"S Edin","year":"2012","unstructured":"Edin, S. et al. The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer. PLoS ONE https:\/\/doi.org\/10.1371\/journal.pone.0047045 (2012).","journal-title":"PLoS ONE"},{"key":"34975_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/jso.21617","author":"JC Kang","year":"2010","unstructured":"Kang, J. C., Chen, J. S., Lee, C. H., Chang, J. J. & Shieh, Y. S. Intratumoral macrophage counts correlate with tumor progression in colorectal cancer. J. Surg. Oncol. https:\/\/doi.org\/10.1002\/jso.21617 (2010).","journal-title":"J. Surg. Oncol."},{"key":"34975_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100502","author":"C Blaye","year":"2022","unstructured":"Blaye, C. et al. An immunological signature to predict outcome in patients with triple-negative breast cancer with residual disease after neoadjuvant chemotherapy. ESMO Open https:\/\/doi.org\/10.1016\/j.esmoop.2022.100502 (2022).","journal-title":"ESMO Open"},{"key":"34975_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5429","author":"H Yin","year":"2023","unstructured":"Yin, H. et al. T cell-inflamed gene expression profile is associated with favorable disease-specific survival in non-hypermutated microsatellite-stable colorectal cancer patients. Cancer Med. https:\/\/doi.org\/10.1002\/cam4.5429 (2023).","journal-title":"Cancer Med."},{"key":"34975_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-80226-z","author":"M Mints","year":"2021","unstructured":"Mints, M. et al. Tumour inflammation signature and expression of S100A12 and HLA class I improve survival in HPV-negative hypopharyngeal cancer. Sci. Rep. https:\/\/doi.org\/10.1038\/s41598-020-80226-z (2021).","journal-title":"Sci. Rep."},{"key":"34975_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.pan.2021.01.025","author":"LG Rasmussen","year":"2021","unstructured":"Rasmussen, L. G. et al. Gene expression profiling of morphologic subtypes of pancreatic ductal adenocarcinoma using surgical and EUS-FNB specimens. Pancreatology https:\/\/doi.org\/10.1016\/j.pan.2021.01.025 (2021).","journal-title":"Pancreatology"},{"key":"34975_CR19","doi-asserted-by":"publisher","DOI":"10.1182\/BLOODADVANCES.2020002512","author":"J Vadakekolathu","year":"2020","unstructured":"Vadakekolathu, J. et al. TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML. Blood Adv. https:\/\/doi.org\/10.1182\/BLOODADVANCES.2020002512 (2020).","journal-title":"Blood Adv."},{"key":"34975_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15184480","author":"MT Mouritzen","year":"2023","unstructured":"Mouritzen, M. T. et al. Gene expressions and high lymphocyte count may predict durable clinical benefits in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors. Cancers https:\/\/doi.org\/10.3390\/cancers15184480 (2023).","journal-title":"Cancers"},{"key":"34975_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-019-2100-3","author":"D Damotte","year":"2019","unstructured":"Damotte, D. et al. The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort. J. Trans. Med. https:\/\/doi.org\/10.1186\/s12967-019-2100-3 (2019).","journal-title":"J. Trans. Med."},{"key":"34975_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2024.02.010","author":"MP Kristensen","year":"2024","unstructured":"Kristensen, M. P. et al. The prognostic value of tumor budding in a thoroughly characterized stage II colon cancer population in the context of a national screening program. Human Pathol. https:\/\/doi.org\/10.1016\/j.humpath.2024.02.010 (2024).","journal-title":"Human Pathol."},{"issue":"8","key":"34975_CR23","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1002\/ijc.35507","volume":"157","author":"U Korsgaard","year":"2025","unstructured":"Korsgaard, U. et al. The prognostic potential of RNA in stage II colon cancer: Insights from a screened multicenter population-based cohort study. Intl Journal of Cancer 157(8), 1746\u20131755. https:\/\/doi.org\/10.1002\/ijc.35507 (2025).","journal-title":"Intl Journal of Cancer"},{"key":"34975_CR24","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abn0238","author":"M Zatzman","year":"2022","unstructured":"Zatzman, M. et al. Widespread hypertranscription in aggressive human cancers. Sci. Adv. https:\/\/doi.org\/10.1126\/sciadv.abn0238 (2022).","journal-title":"Sci. Adv."},{"issue":"9","key":"34975_CR25","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nri.2017.49","volume":"17","author":"N Nagarsheth","year":"2017","unstructured":"Nagarsheth, N., Wicha, M. S. & Zou, W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat. Rev. Immunol. 17(9), 559\u2013572. https:\/\/doi.org\/10.1038\/nri.2017.49 (2017).","journal-title":"Nat. Rev. Immunol."},{"key":"34975_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2015.06.024","author":"E Chun","year":"2015","unstructured":"Chun, E. et al. CCL2 Promotes Colorectal Carcinogenesis by Enhancing Polymorphonuclear Myeloid-Derived Suppressor Cell Population and Function. Cell Rep. https:\/\/doi.org\/10.1016\/j.celrep.2015.06.024 (2015).","journal-title":"Cell Rep."},{"key":"34975_CR27","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.8.5791","author":"J-I Youn","year":"2008","unstructured":"Youn, J.-I., Nagaraj, S., Collazo, M. & Gabrilovich, D. I. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. The J. Immunol. https:\/\/doi.org\/10.4049\/jimmunol.181.8.5791 (2008).","journal-title":"The J. Immunol."},{"key":"34975_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/nri2506","author":"DI Gabrilovich","year":"2009","unstructured":"Gabrilovich, D. I. & Nagaraj, S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. https:\/\/doi.org\/10.1038\/nri2506 (2009).","journal-title":"Nat. Rev. Immunol."},{"key":"34975_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-62416-x","author":"TM Pausch","year":"2020","unstructured":"Pausch, T. M. et al. Metastasis-associated fibroblasts promote angiogenesis in metastasized pancreatic cancer via the CXCL8 and the CCL2 axes. Sci. Rep. https:\/\/doi.org\/10.1038\/s41598-020-62416-x (2020).","journal-title":"Sci. Rep."},{"key":"34975_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/cjp2.290","author":"KAF Pennel","year":"2022","unstructured":"Pennel, K. A. F. et al. CXCL8 expression is associated with advanced stage, right sidedness, and distinct histological features of colorectal cancer. J. Pathol. Clin. Res. https:\/\/doi.org\/10.1002\/cjp2.290 (2022).","journal-title":"J. Pathol. Clin. Res."},{"key":"34975_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6218","author":"H Yu","year":"2014","unstructured":"Yu, H. et al. LIF negatively regulates tumour-suppressor p53 through Stat3\/ID1\/MDM2 in colorectal cancers. Nat. Commun. https:\/\/doi.org\/10.1038\/ncomms6218 (2014).","journal-title":"Nat. Commun."},{"key":"34975_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/nrm757","author":"MA Nieto","year":"2002","unstructured":"Nieto, M. A. The snail superfamily of zinc-finger transcription factors. Nat. Rev. Mol. Cell Biol. https:\/\/doi.org\/10.1038\/nrm757 (2002).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"34975_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2012.03.029","author":"XJ Fan","year":"2013","unstructured":"Fan, X. J. et al. Snail promotes lymph node metastasis and Twist enhances tumor deposit formation through epithelial-mesenchymal transition in colorectal cancer. Human Pathol. https:\/\/doi.org\/10.1016\/j.humpath.2012.03.029 (2013).","journal-title":"Human Pathol."},{"issue":"2","key":"34975_CR34","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/(SICI)1098-1004(1997)10:2<89::AID-HUMU1>3.0.CO;2-H","volume":"10","author":"N Papadopoulos","year":"1997","unstructured":"Papadopoulos, N. & Lindblom, A. Molecular basis of HNPCC: Mutations of MMR genes. Hum. Mutat. 10(2), 89\u201399. https:\/\/doi.org\/10.1002\/(SICI)1098-1004(1997)10:2%3c89::AID-HUMU1%3e3.0.CO;2-H (1997).","journal-title":"Hum. Mutat."},{"key":"34975_CR35","doi-asserted-by":"publisher","DOI":"10.1126\/science.3103217","author":"JS Flier","year":"1987","unstructured":"Flier, J. S., Mueckler, M. M., Usher, P. & Lodish, H. F. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science https:\/\/doi.org\/10.1126\/science.3103217 (1987).","journal-title":"Science"},{"key":"34975_CR36","doi-asserted-by":"publisher","DOI":"10.1158\/jcr.1925.148","author":"O Warburg","year":"1925","unstructured":"Warburg, O. The metabolism of carcinoma cells. Cancer Res. https:\/\/doi.org\/10.1158\/jcr.1925.148 (1925).","journal-title":"Cancer Res."},{"key":"34975_CR37","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.jcrt_42_21","author":"S Vasudevan","year":"2022","unstructured":"Vasudevan, S., Mehta, A., Sharma, S. K. & Sharma, A. Expression of glucose transporter 1 (SLC2A1) - Clinicopathological associations and survival in an Indian cohort of colorectal cancer patients. J. Cancer Res. Ther. https:\/\/doi.org\/10.4103\/jcrt.jcrt_42_21 (2022).","journal-title":"J. Cancer Res. Ther."},{"key":"34975_CR38","doi-asserted-by":"publisher","DOI":"10.5301\/JBM.2011.8550","author":"YM Shen","year":"2011","unstructured":"Shen, Y. M., Arbman, G., Olsson, B. & Sun, X. F. Overexpression of GLUT1 in colorectal cancer is independently associated with poor prognosis. Inter. J. Biol. Markers https:\/\/doi.org\/10.5301\/JBM.2011.8550 (2011).","journal-title":"Inter. J. Biol. Markers"},{"key":"34975_CR39","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/(SICI)1097-0142(19980701)83:1<34::AID-CNCR5>3.0.CO;2-E","volume":"83","author":"RS Haber","year":"1998","unstructured":"Haber, R. S. et al. GLUT1 glucose transporter expression in colorectal carcinoma: A marker for poor prognosis. Cancer 83, 34\u201340 (1998).","journal-title":"Cancer"},{"key":"34975_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-300511","author":"M De Wit","year":"2012","unstructured":"De Wit, M. et al. Cell surface proteomics identifies glucose transporter type 1 and prion protein as candidate biomarkers for colorectal adenoma-to-carcinoma progression. Gut https:\/\/doi.org\/10.1136\/gutjnl-2011-300511 (2012).","journal-title":"Gut"},{"key":"34975_CR41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.081","author":"DJ Hicklin","year":"2005","unstructured":"Hicklin, D. J. & Ellis, L. M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO.2005.06.081 (2005).","journal-title":"J. Clin. Oncol."},{"key":"34975_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603176","author":"G Des Guetz","year":"2006","unstructured":"Des Guetz, G. et al. Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Brit. J. Cancer https:\/\/doi.org\/10.1038\/sj.bjc.6603176 (2006).","journal-title":"Brit. J. Cancer"},{"issue":"7","key":"34975_CR43","doi-asserted-by":"publisher","first-page":"763","DOI":"10.2217\/pgs.12.38","volume":"13","author":"S Kjaer-Frifeldt","year":"2012","unstructured":"Kjaer-Frifeldt, S. et al. Prognostic importance of VEGF-A haplotype combinations in a stage II colon cancer population. Pharmacogenomics 13(7), 763\u2013770. https:\/\/doi.org\/10.2217\/pgs.12.38 (2012).","journal-title":"Pharmacogenomics"},{"key":"34975_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70477-1","author":"J Bennouna","year":"2013","unstructured":"Bennouna, J. et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): A randomised phase 3 trial. The Lancet Oncol. https:\/\/doi.org\/10.1016\/S1470-2045(12)70477-1 (2013).","journal-title":"The Lancet Oncol."},{"key":"34975_CR45","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.6305","author":"BJ Giantonio","year":"2007","unstructured":"Giantonio, B. J. et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO.2006.09.6305 (2007).","journal-title":"J. Clin. Oncol."},{"key":"34975_CR46","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa032691","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New England J. Med. https:\/\/doi.org\/10.1056\/nejmoa032691 (2004).","journal-title":"New England J. Med."},{"issue":"3","key":"34975_CR47","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1200\/JCO.2012.44.4711","volume":"31","author":"CJ Allegra","year":"2013","unstructured":"Allegra, C. J. et al. Bevacizumab in Stage II-III Colon Cancer: 5-Year Update of the National Surgical Adjuvant Breast and Bowel Project C-08 Trial. JCO 31(3), 359\u2013364. https:\/\/doi.org\/10.1200\/JCO.2012.44.4711 (2013).","journal-title":"JCO"},{"issue":"10","key":"34975_CR48","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.20425","volume":"3","author":"B Chibaudel","year":"2020","unstructured":"Chibaudel, B. et al. Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial. JAMA Netw Open 3(10), e2020425. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.20425 (2020).","journal-title":"JAMA Netw Open"},{"issue":"12","key":"34975_CR49","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/S1470-2045(12)70509-0","volume":"13","author":"A De Gramont","year":"2012","unstructured":"De Gramont, A. et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol. 13(12), 1225\u20131233. https:\/\/doi.org\/10.1016\/S1470-2045(12)70509-0 (2012).","journal-title":"Lancet Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34975-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34975-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34975-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T10:51:45Z","timestamp":1770634305000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34975-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["34975"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-34975-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"22 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5454"}}